Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program

Autor: Procopio, Giuseppe, Prisciandaro, Michele, Iacovelli, Roberto, Cortesi, Enrico, Fornarini, Giuseppe, Facchini, Gaetano, Cartenì, Giacomo, Sabbatini, Roberto, Del Bene, Gabriella, Galli, Luca, Caserta, Claudia, Multari, Andrea Giovanni, Bregni, Marco, Massari, Francesco, Buti, Sebastiano, De Giorgi, Ugo, Zustovich, Fable, Milella, Michele, Calabrò, Fabio, Mancini, Maria Laura, Tortora, Giampaolo, Vernieri, Claudio, Santini, Daniele, Sorarù, Mariella, Ricotta, Riccardo, Masini, Cristina, Tucci, Marcello, Fedeli, Stefano Luzi, Ortega, Cinzia, Mecozzi, Antonella, Ratta, Raffaele, Sternberg, Cora N., Verzoni, Elena

Publikováno v: In Clinical Genitourinary Cancer August 2018 16(4):e945-e951

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials

Autor: Daniele Generali, Chiara Pacifico, Giandomenico Roviello, Andrea Giovanni Multari, Angela Gobbi, Giulia Borsella, Laura Zanotti, Maria Rosa Cappelletti

Publikováno v: Critical Reviews in Oncology/Hematology. 108:62-68

Several new biological agents have been investigated as second line of treatment in advanced Hepatocellular Cancer (HCC). We performed a meta -analysis to assess the effect of targeted therapies in advanced HCC patients beyond the first line of treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a16fa4d5d27c2647abf0a2d8dd067686
https://doi.org/10.1016/j.critrevonc.2016.10.015

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

Autor: Roviello G; Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero, Vulture (PZ), Italy., Corona SP; Peter MacCallum Cancer Centre, Radiation Oncology Department, Moorabbin Campus, East Bentleigh, Victoria 3165, Australia., Multari AG; Unit of Medical Oncology, Department of Oncology, Ospedale San Donato, 52100, Arezzo, Italy., Paganini G; Unit of general medicine, Azienda Ospedaliera 'C. Poma' Presidio ospedaliero di Pieve di Coriano, ASST Mantova, Italy., Chiriacò G; Medical Oncology Unit, Department of Oncology, ASST del Garda, 25015 Desenzano del Garda (BS), Italy., Conca R; Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero, Vulture (PZ), Italy., Petrioli R; Department of Medicine, Surgery and Neurosciences, Medical Oncology Unit, University of Siena, Viale Bracci - Policlinico 'Le Scotte', 53100, Siena, Italy., Generali D; Department of Medical, Surgery and Health Sciences, University of Trieste, 34129 Trieste, Italy.; Breast Cancer and Translational Research Unit, ASST Cremona, 26100 Cremona, Italy., Rosellini P; Department of Medicine, Surgery and Neurosciences, Medical Oncology Unit, University of Siena, Viale Bracci - Policlinico 'Le Scotte', 53100, Siena, Italy., Aieta M; Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero, Vulture (PZ), Italy.

Publikováno v: Oncotarget [Oncotarget] 2018 Apr 27; Vol. 9 (32), pp. 22332-22339. Date of Electronic Publication: 2018 Apr 27 (Print Publication: 2018).